Literature DB >> 16888289

Tricuspid annular displacement predicts survival in pulmonary hypertension.

Paul R Forfia1, Micah R Fisher, Stephen C Mathai, Traci Housten-Harris, Anna R Hemnes, Barry A Borlaug, Elzbieta Chamera, Mary C Corretti, Hunter C Champion, Theodore P Abraham, Reda E Girgis, Paul M Hassoun.   

Abstract

RATIONALE: Right ventricular (RV) function is an important determinant of prognosis in pulmonary hypertension. However, noninvasive assessment of the RV function is often limited by complex geometry and poor endocardial definition.
OBJECTIVES: To test whether the degree of tricuspid annular displacement (tricuspid annular plane systolic excursion [TAPSE]) is a useful echo-derived measure of RV function with prognostic significance in pulmonary hypertension.
METHODS: We prospectively studied 63 consecutive patients with pulmonary hypertension who were referred for a clinically indicated right heart catheterization. Patients underwent right heart catheterization immediately followed by transthoracic echocardiogram and TAPSE measurement.
RESULTS: In the overall cohort, a TAPSE of less than 1.8 cm was associated with greater RV systolic dysfunction (cardiac index, 1.9 vs. 2.7 L/min/m2; RV % area change, 24 vs. 33%), right heart remodeling (right atrial area index, 17.0 vs. 12.1 cm(2)/m), and RV-left ventricular (LV) disproportion (RV/LV diastolic area, 1.7 vs. 1.2; all p < 0.001), versus a TAPSE of 1.8 cm or greater. In patients with pulmonary arterial hypertension (PAH; n = 47), survival estimates at 1 and 2 yr were 94 and 88%, respectively, in those with a TAPSE of 1.8 cm or greater versus 60 and 50%, respectively, in subjects with a TAPSE less than 1.8 cm. The unadjusted risk of death (hazard ratio) in patients with a TAPSE less than 1.8 versus 1.8 cm or greater was 5.7 (95% confidence interval, 1.3-24.9; p = 0.02) for the PAH cohort. For every 1-mm decrease in TAPSE, the unadjusted risk of death increased by 17% (hazard ratio, 1.17; 95% confidence interval, 1.05-1.30; p = 0.006), which persisted after adjusting for other echocardiographic and hemodynamic variables and baseline treatment status.
CONCLUSIONS: TAPSE powerfully reflects RV function and prognosis in PAH.

Entities:  

Mesh:

Year:  2006        PMID: 16888289     DOI: 10.1164/rccm.200604-547OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  255 in total

1.  It is time to look at heart failure with preserved ejection fraction from the right side.

Authors:  Neal A Chatterjee; Johannes Steiner; Gregory D Lewis
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

Review 2.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 3.  An update on the evaluation and management of pulmonary hypertension in scleroderma.

Authors:  John G Coghlan; Benjamin Schreiber; Benjamin Schrieber
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 4.  Redefining the role of cardiovascular imaging in patients with pulmonary arterial hypertension.

Authors:  Benjamin H Freed; Amit R Patel; Roberto M Lang
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

Review 5.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 6.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 7.  Imaging the right ventricle--current state of the art.

Authors:  Luc L Mertens; Mark K Friedberg
Journal:  Nat Rev Cardiol       Date:  2010-08-10       Impact factor: 32.419

8.  Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension.

Authors:  Veronika Wetzl; Svenja Lena Tiede; Lothar Faerber; Norbert Weissmann; Ralph Theo Schermuly; Hossein Ardeschir Ghofrani; Henning Gall
Journal:  Lung       Date:  2017-05-17       Impact factor: 2.584

9.  Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension: indications for a seminal role for mitochondrial Nox4.

Authors:  Giovanna Frazziano; Imad Al Ghouleh; Jeff Baust; Sruti Shiva; Hunter C Champion; Patrick J Pagano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-08       Impact factor: 4.733

Review 10.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.